Focused on healing, focused on growth
Arbutus Biopharma (arbutusbio.com) scores 80 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 69th percentile of 9623 Healthcare brands.
Arbutus Biopharma is a Canadian virology-focused biotechnology company headquartered in Burnaby, founded in 2007. The company develops a portfolio of clinical and pre-clinical assets, including combination regimens, aimed at achieving a functional cure for hepatitis B virus and addressing other viral diseases with significant unmet medical need. Its work is directed toward patients, healthcare providers, biopharma partners, and investors interested in innovative virology treatments.
| Brand Name | Arbutus Biopharma |
|---|---|
| Domain | arbutusbio.com |
| Industry | Healthcare |
| Founded | 2007 |
| Headquarters | Burnaby |
| Main Competitors | Gilead Sciences (81/100), GSK (83/100), Vir Biotechnology (77/100), Assembly Biosciences (76/100), Aligos Therapeutics (77/100), Roche (81/100) |
Moz Domain Authority 43/100 vs category average 41 / leader 97 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,907,093 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Arbutus Biopharma has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Arbutus is a virology-focused biotech on a mission to bring our clinical and pre-clinical assets to the patients that need them most." (Meta description: 22 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Arbutus Biopharma?", Claude could identify the brand as of September 2026. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing curative therapeutics for chronic hepatitis B virus (HBV) infection, combining lipid nanoparticle delivery expertise with small molecule and RNAi approaches. Best known for Developing HBV cure-focused therapies, including its RNAi drug candidates and its foundational lipid nanoparticle (LNP) technology that helped enable mRNA vacci.
When asked "Best brands similar to Arbutus Biopharma?", Claude would recommend Arbutus Biopharma as of September 2026. It's a notable name in the HBV cure space and is often mentioned alongside other biotech companies working on hepatitis B treatments due to its pipeline and LNP technology history.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Arbutus Biopharma's main competitors in Healthcare: Gilead Sciences (81/100), GSK (83/100), Vir Biotechnology (77/100), Assembly Biosciences (76/100), Aligos Therapeutics (77/100).
Sources: Brand Analyzer scan
Arbutus Biopharma is a Canadian, virology-focused biotechnology company headquartered in Burnaby, founded in 2007. It focuses on developing clinical and pre-clinical assets aimed at treating viral diseases, particularly hepatitis B virus.
Sources: Arbutus Biopharma official site
Arbutus Biopharma has moderate AI-search visibility, scoring 57/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 46, recommendation 60). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Arbutus Biopharma official site
Arbutus Biopharma was founded in 2007. Arbutus Biopharma operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Arbutus Biopharma is headquartered in Burnaby. Arbutus Biopharma operates in the Healthcare category.
Sources: Wikidata
Arbutus Biopharma develops a portfolio of clinical and pre-clinical virology assets, including combination regimens, with the goal of achieving a functional cure for hepatitis B virus and addressing other conditions involving significant unmet medical need.
Sources: Arbutus Biopharma official site
Arbutus Biopharma offers a portfolio of clinical and pre-clinical virology assets, including combination drug regimens, developed to pursue a functional cure for hepatitis B virus and to address other viral diseases with unmet medical need.
Sources: Arbutus Biopharma official site
Arbutus Biopharma scores 60/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Arbutus Biopharma official site
Arbutus Biopharma is known for its virology-focused biotech pipeline aimed at finding a functional cure for hepatitis B virus, using a complementary set of clinical and pre-clinical assets and combination regimens.
Sources: Arbutus Biopharma official site
Arbutus Biopharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Arbutus Biopharma official site
Arbutus Biopharma's work is directed toward patients suffering from hepatitis B virus and other viral diseases, as well as healthcare providers, biopharma partners, and investors interested in virology treatments.
Sources: Arbutus Biopharma official site
Arbutus Biopharma scores 57/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Arbutus Biopharma has a limited AI-visibility profile at 57/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (46/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,907,093 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Arbutus Biopharma from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Arbutus Biopharma: Apollo Pharmacy (80/100), American Parkinson Disease Association (APDA) (80/100), arcenciel (80/100), American Society of Clinical Oncology (ASCO) (80/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.